For COVID-19 and vaccination updates, view our information for the community. If you're experiencing symptoms, call your primary care provider.
A Phase 1B/2, First-In-Human, Dose Escalation And Expansion Study Of XMT-1536 In Patients With Solid Tumors Likely To Express NAPI2B
The purpose of testing your tumor samples for levels of the NaPi2b protein or RNA is to evaluate whether this testing can be used as a tool to help determine if a patient’s cancer will respond to treatment for future patients prior to their dosing with XMT-1536.
DiagnosisPatients who have been diagnosed with one of the following NaPi2b (sodium-dependent phosphate transporter)-expressing cancers: • Platinum-resistant high-grade serous ovarian cancer Prior treatments have not worked (or have stopped working) against your cancer and it has continued to grow.
Platinum resistant ovarian cancer (1-3 prior lines) or any recurrent ovarian cancer patient who has had 4 or more prior therapies.
Must be high-grade serous.
Measurable disease required.
No more than 2 prior lines containing taxane.
Patients must sign an approved informed consent and authorization permitting release of personal health information.
Open-Label XMT-1536 every 28 days until progression
For more information, visit ClinicalTrials.gov